Edition:
United States

Eleven Biotherapeutics Inc (EBIO.OQ)

EBIO.OQ on NASDAQ Stock Exchange Global Market

0.66USD
3:59pm EST
Change (% chg)

$0.01 (+0.86%)
Prev Close
$0.65
Open
$0.65
Day's High
$0.67
Day's Low
$0.65
Volume
50,801
Avg. Vol
105,122
52-wk High
$2.53
52-wk Low
$0.63

Latest Key Developments (Source: Significant Developments)

Eleven Biotherapeutics reports Q3 loss per share $0.37
Monday, 20 Nov 2017 08:30am EST 

Nov 20 (Reuters) - Eleven Biotherapeutics Inc :Eleven Biotherapeutics reports third quarter 2017 financial results.Q3 loss per share $0.37.Eleven Biotherapeutics Inc - ‍topline 3-month data from phase 3 trial of Vicinium on track for mid-2018​.Eleven Biotherapeutics - did not record any revenue for three months ended September 30, 2017, compared to revenue of $28.7 million for same period in 2016​.Eleven Biotherapeutics - ‍anticipates cash at Sept 30, net $7.0 million raised in Nov will fund research, development programs, operations into mid-2018​.  Full Article

Eleven Biotherapeutics says expects to report no revenue ‍for 3 months ended Sept 30
Thursday, 16 Nov 2017 09:01am EST 

Nov 16 (Reuters) - Eleven Biotherapeutics Inc -:Eleven Biotherapeutics - ‍for 3 months ended Sept 30, co expects to report no revenue compared to $28.7 million in revenue for 3 months ended Sept 30, 2016​.Eleven Biotherapeutics - ‍intends to make accounting adjustments in financial statements in connection with finalization of accounting of Viventia deal ​.  Full Article

Eleven Biotherapeutics CFO steps down; Richard Fitzgerald named interim CFO
Friday, 13 Oct 2017 04:30pm EDT 

Oct 13 (Reuters) - Eleven Biotherapeutics Inc -:Eleven Biotherapeutics appoints Richard Fitzgerald as interim chief financial officer.Eleven Biotherapeutics Inc - ‍ John McCabe, who currently holds chief financial officer position, will be stepping down​.  Full Article

Eleven Biotherapeutics ‍appoints Richard Fitzgerald as interim CFO
Friday, 13 Oct 2017 04:17pm EDT 

Oct 13 (Reuters) - Eleven Biotherapeutics Inc :Eleven Biotherapeutics Inc - ‍appointed Richard F. Fitzgerald, age 54, as company's interim Chief Financial Officer, effective October 13, 2017​.Eleven Biotherapeutics Inc - ‍on October 6, 2017, John J. McCabe resigned as Chief Financial Officer of company, effective as of October 20, 2017​.  Full Article

Eleven Biotherapeutics files for offering of $12.5 mln common stock
Wednesday, 4 Oct 2017 05:28pm EDT 

Oct 4 (Reuters) - Eleven Biotherapeutics Inc :Eleven biotherapeutics inc- files for offering of $12.5 million common stock.  Full Article

Eleven Biotherapeutics Q2 loss per share $0.30
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Eleven Biotherapeutics Inc :Eleven Biotherapeutics reports second quarter 2017 financial results.Q2 loss per share $0.30.Eleven Biotherapeutics Inc - expects to have cash to fund research and development programs and operations into early 2018..  Full Article

Eleven Biotherapeutics to collaborate with Astrazeneca, National Cancer Institute
Tuesday, 6 Jun 2017 08:00am EDT 

June 6 (Reuters) - Eleven Biotherapeutics Inc ::Eleven Biotherapeutics to collaborate with Astrazeneca and National Cancer Institute on development of vicinium in combination with durvalumab.Eleven Biotherapeutics Inc says vicinium is currently in a phase 3 registration trial for treatment of high-grade NMIBC.Eleven Biotherapeutics - for phase 3 expects to complete patient enrollment in second half of 2017, and to report topline 3-month data in Q2 of 2018.Says the combination drug is for treatment of non-muscle invasive bladder cancer.  Full Article

Eleven Biotherapeutics recommends safety monitoring board to continue phase 3 registration trial with Vicinium
Thursday, 1 Jun 2017 08:00am EDT 

June 1 (Reuters) - Eleven Biotherapeutics Inc :Eleven Biotherapeutics announces Data and Safety Monitoring Board (DSMB) recommendation to continue phase 3 registration trial with vicinium™ in non-muscle invasive bladder cancer based on review of safety and efficacy data.Eleven Biotherapeutics Inc says expects to complete patient enrollment in 2H2017 and to report topline 3-month data in 2Q2018.Says DSMB recommended that trial continue without modification.Eleven Biotherapeutics Inc - plans to enroll 134 patients for trial, at over 70 centers in United States and Canada.  Full Article

ELEVEN BIOTHERAPEUTICS Q1 LOSS PER SHARE $0.25
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Eleven Biotherapeutics Inc :ELEVEN BIOTHERAPEUTICS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.25.Q1 REVENUE $400,000 VERSUS $200,000.ELEVEN BIOTHERAPEUTICS INC - EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO EARLY 2018.  Full Article

Eleven Biotherapeutics reports Q4 loss per share $0.15
Friday, 24 Mar 2017 07:00am EDT 

Eleven Biotherapeutics Inc : Eleven Biotherapeutics reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.15 . Q4 revenue $800,000 versus $600,000 . Eleven Biotherapeutics Inc- cash and cash equivalents were $25.3 million as of December 31, 2016, compared to $36.1 million as of December 31, 2015 . Eleven Biotherapeutics Inc- Eleven expects to have cash to fund research and development programs and operations into early 2018. .Eleven Biotherapeutics - topline phase 3 data for lead drug candidate vicinium, in development for non-muscle invasive bladder cancer, expected in 2018.  Full Article